New pill aims to let people with 'Sun Allergy' enjoy daylight
NCT ID NCT05308472
Summary
This study tested whether an oral drug called bitopertin could help adults with erythropoietic protoporphyria (EPP), a condition causing severe pain from sunlight exposure. For about 4 months, 75 participants received either the real drug or a placebo pill to see if it reduced pain and lowered levels of a harmful light-sensitive chemical in their blood. The main goal was to see if people could spend more time in the sun without experiencing burning or stinging pain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
Einstein Medical Center
Philadelphia, Pennsylvania, 19141, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
University of Alabama Hospital
Birmingham, Alabama, 35233, United States
-
University of California San Francisco
San Francisco, California, 94117, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
-
University of Texas
Galveston, Texas, 77550, United States
Conditions
Explore the condition pages connected to this study.